Msd

4D Pharma expanding clinical data in multiple indications

28-Jun-2021 By Jane Byrne

Live biotherapeutic product (LBP) developer, 4D Pharma, says it is building a ‘strong body of evidence’ for its portfolio of bacterial strains in relation to cancer, asthma, and neurodegenerative diseases, while the company also calls its recent dual...

FDA rebuff for Keytruda in breast cancer indication

30-Mar-2021 By Jane Byrne

A couple of new developments to report in relation to Merck, known as MSD outside the US and Canada: the first being the rejection by the US FDA of the company’s application to use its anti-PD-1 therapy, Keytruda, in certain breast cancer patients.

Merck partners for ‘blockbuster’ vaccine target

26-Aug-2019 By Vassia Barba

Themis obtains an exclusive licence from Merck to develop vaccine candidates with an undisclosed indication, using its measles virus vector-based platform.

Merck continues to expand oncology pipeline with $773m deal

11-Jun-2019 By Vassia Barba & Ben Hargreaves

Merck acquires Tilos, a biopharmaceutical developer targeting the latent TGFβ complex for the treatment of cancer, fibrosis and autoimmune diseases.

Merck bumps up production of MMR vaccine amid measles outbreak

08-May-2019 By Maggie Lynch

With the recent outbreak of measles in the US, the only MMR vaccine producer in the US, Merck, has increased its production to meet demand.

Merck extends research agreement for NASH drug candidate

27-Mar-2019 By Maggie Lynch

Merck exercises its option to extend research phase with NGM for an additional two-year period, moving the collaboration end date to March 2022.

MSD adds vaccine and biologics facility next to Keytruda site, creates 170 jobs

17-Oct-2018 By Flora Southey

MSD will build a second manufacturing plant in County Carlow, Ireland, in response to growing demand.